The FOLFIRINOX regimen (folinic acid, fluorouracil, irinotecan, and oxaliplatin) remains the treatment of choice for patients with pancreatic cancer even as clinical trials exploring potential therapies, including CD40 and CPI-613, offer the possibility of new options for a notoriously difficult-to-treat disease, Davendra P.S. Sohal, MD, MPH, told an audience at the 2019 Gastrointestinal Oncology Conference.
Sohal, an assistant professor, director of experimental therapeutics, and clinic medical director at the University of Cincinnati, said FOLFIRINOX is the easy answer for every patient with pancreatic cancer in the adjuvant, neoadjuvant, and metastatic settings. The regimen is effective, according to the results of a phase III trial published in The New England Journal of Medicine (NEJM)…Read more . . .